Featured Articles From The Current Issue
SPECIAL FEATURE - Injectable Drug Delivery: Key Trends Define Device Design Now & in the Future
Contributor Cindy H. Dubin spoke with some of the world’s leading device developers about their current injection technologies and how their devices are addressing the current trends and opportunities in the industry.


>>> See All Cover Stories

Tom Reynolds, PhD, Matt Wessel, PhD, Sanjay Konagurthu, PhD, and Marshall Crew, PhD, report that computational methods, such as QM and MD simulations, are playing an ever-expanding role in drug discovery and development, and transforming advances in drug development at all stages.
Ronak Savla, PhD, PharmD, and Jeffrey E. Browne, PhD, indicate formulation screening, development, scale-up, and commercial manufacture of LBDDSs require considerable expertise, and choosing an outsourcing partner with experience and a proven track record is critical.
Anthony Recupero, PhD, believes by partnering with an expert in drug delivery technology, whose portfolio features a broad range of proprietary technologies, pharmaceutical companies have the potential to add further value to their products and extend market exclusivity.
Kathryn A. Lee, PhD; Markus Lankers, PhD; and Oliver Valet, PhD, discuss various aspects with regard to microscopic particle counting, sizing, and identification using Raman, laser-induced breakdown, and IR spectroscopies, and how these techniques can help accurately identify particles.
Rick Pauls, MBA, says treatment of ischemic strokes hinges on getting tPA into the patient within just few hours of the stroke occurring, but getting to the hospital quickly requires a great deal of luck, and anything that buys the patient more time is worth pursuing.
Dr. Stephan Kutzer, CEO, President, and Chairman of Alcami, discusses his company’s business strategy, outsourcing trends, how the company meets the growing needs of customers, and why companies choose Alcami.
John A. Bermingham says not every product, technology, or service is intended for international trade. But then again, not every business is intended to stay at home either.
The Global Formulation Report in this issue provided some interesting data on what has been happening in a number of key sectors over the past year. We thought it would be intriguing to hear what some of your colleagues said surprised them most.
Robert Lins, MD, PhD, believes classical primary respiratory endpoints are far from successful in exploratory and confirmatory studies, and new techniques being developed have most potential in early phase, exploratory, clinical trials, but there may be the opportunity to apply at least some of them in the later stages of development.
Lilli Zakarija, MSME, MBA, explains that in order to conduct a successful V&V on the intended combination product, the key is to understand that the V&V testing is not an isolated activity and task.
Roelof Rongen, MBA, MS, indicates drugs for serious fungal and microbial infections currently require IV administration at doses associated with significant toxicity. Orally administered, encochleated formulations of a broad-spectrum of fungicidal and anti-microbial medications may provide delivery of anti-infective drugs at therapeutic levels while minimizing drug-associated side effects.
Jeffrey Bacha, Chairman & CEO of DelMar Pharmaceuticals, discusses his company’s unique approach to developing VAL-083, the challenges in working within cancer indications associated with low survival, and the importance of strategic collaborations with universities and organizations to further develop its technology.
Exclusive Online Content
​Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening​Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening
Adare Pharmaceuticals, a private global specialty pharmaceutical company, celebrated the official opening of its Corporate Headquarters located at 1200 Lenox Drive in Lawrenceville, New Jersey.

"Engineering Medicines to Life" Campaign Highlights Capsugel's Unique Positioning as Specialty CDMO"Engineering Medicines to Life" Campaign Highlights Capsugel's Unique Positioning as Specialty CDMO
After successfully completing four transformational acquisitions, as well as several other strategic investments, Capsugel today announced that it has unified them all under one brand and unveiled a new corporate campaign that highlights the company’s expanded capabilities for the design, development and manufacture of a wide range of innovative dosage forms.

Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration
Bristol-Myers Squibb Company and Nektar Therapeutics recently announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a potential combination treatment regimen in five tumor types and seven potential indications.

Australian Pharmaceutical Market to Surpass $25 Billion Australian Pharmaceutical Market to Surpass $25 Billion
Australia’s pharmaceutical market is set to rise from just over $22.85 billion in 2016 to $25.2 billion by 2020, registering a compound annual growth rate (CAGR) of 2%, according to research and consulting firm GlobalData.

Virtual Pharma Companies: The Future is Now Virtual Pharma Companies: The Future is Now
Given a number of continuing industry pressures — including greater diversity of pharma R&D sponsors, looming patent expirations and increased focus on outcomes-based patient care — the virtual pharmaceutical model is proving to be successful, says Tom Salus, director of sales at Metrics Contract Services.

Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based ProductsAmyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
Amyris, Inc., the industrial bioscience company, recently announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved by the boards of both companies.

Voyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of TechnologyVoyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of Technology
Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), recently announced a co-exclusive worldwide license agreement with the California Institute of Technology (Caltech) related to novel adeno-associated virus (AAV) capsids.

Epizyme Earns $6-Million Milestone Payment From GlaxoSmithKline Epizyme Earns $6-Million Milestone Payment From GlaxoSmithKline
Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, recently announced it has earned a $6-million milestone payment from GlaxoSmithKline (GSK).

Gerresheimer to Sell Life Science Research Business Gerresheimer to Sell Life Science Research Business
In line with its strategy of focusing on packaging and device solutions for pharmaceutical customers, Gerresheimer recently announced that it is to sell its Life Science Research business to Duran group, a portfolio company of One Equity Partners.

Bayer Clinches Monsanto With Improved $66-Billion BidBayer Clinches Monsanto With Improved $66-Billion Bid
German drugs and crop chemicals company Bayer has won over US seeds firm Monsanto with an improved takeover offer of around $66 billion, ending months of wrangling after increasing its bid for a third time.
Market News & Trends
 



Copyright © 2016  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions